Tumor fraction-based prognostic tool for cancer patients referred to early phase clinical trials.

Selecting patients for phase I cancer trials is crucial to ensure a sufficient life expectancy. Frail patients, better suited for palliative care, should not be exposed to new drugs with minimal benefit. Enrolling patients at high risk of early death can jeopardize the study.

Characterization of the novel HLA-DPB1*1139:01 allele by sequencing-based typing.

HLA-DPB1*1139:01 differs from HLA-DPB1*04:01:01:03 by one nucleotide substitution in codon 15 in exon 2.

Characterization of the novel HLA-DRB1*11:282 allele by sequencing-based typing.

HLA-DRB1*11:282 differs from HLA-DRB1*11:04:01:01 by one nucleotide substitution in codon 41 in exon 2.

Characterization of the novel HLA-C*05:01:58 allele by sequencing-based typing.

HLA-C*05:01:58 differs from HLA-C*05:01:01:02 by a single nucleotide change in codon 112 in exon 3.

Characterization of the novel HLA-A*36:12 allele by sequencing-based typing.

HLA-A*36:12 differs from HLA-A*36:01:01:01 by one nucleotide substitution in codon 211 in exon 4.

Characterization of the novel HLA-DQA1*03:20 allele by sequencing-based typing.

HLA-DQA1*03:20 differs from HLA-DQA1*03:03:01:01 by one nucleotide substitution in codon 33 in exon 2.

Characterization of the novel HLA-A*01:367 allele by sequencing-based typing.

HLA-A*01:367 differs from HLA-A*01:01:01:01 by one nucleotide substitution in codon 271 in exon 4.

Characterization of the novel HLA-C*06:314 allele by sequencing-based typing.

HLA-C*06:314 differs from HLA-C*06:02:01:01 by one nucleotide substitution in codon 327 in exon 7.

Characterization of the novel HLA-DPA1*01:44 allele by sequencing-based typing.

HLA-DPA1*01:44 differs from DPA1*01:03:01:04 by one nucleotide substitution in codon 175 in exon 3.

Immunization against α β and α β in Glanzmann thrombasthenia patients carrying the French Gypsy mutation.

Essentials The c.1544+1G>A mutation was identified in Gypsy Glanzmann thrombasthenia (GT) patients. Gypsy GT patients express normal α β carrying HPA-1b epitopes.

Characterization of the novel HLA-DQB1*04:78 allele by sequencing-based typing.

HLA-DQB1*04:78 differs from HLA-DQB1*04:02:01:04 by one nucleotide substitution in codon 95 in exon 3.

Characterization of the novel HLA-DRB3*01:86 allele by sequencing-based typing.

HLA-DRB3*01:86 differs from HLA-DRB3*01:01:02:01 by one nucleotide substitution in codon 225 in exon 4.

Improvement in HLA-C typing by a new sequence-specific oligonucleotides kit.

PCR-sequence-specific oligonucleotide (PCR-SSO) is commonly used for HLA-typing. We recently replaced LabType SSO HD kit for HLA-C typing with the XR kit (OneLambda, Inc.).

[Relevance of antibodies in hematopoietic stem cell transplantation: Antibodies anti-HLA, anti-platelets, anti-granulocytes, anti-erythrocytes and anti-MICA. Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].

The presence of allo-antibodies in the serum of a recipient awaiting hematopoietic stem cell transplantation (HSCT) may have an impact on transfusion efficiency and/or donor choice, especially in the absence of an identical sibling donor. Prior to transplantation, donor specific anti-HLA (Human Leukocyte Antigen) antibodies (DSA) have a recognized effect on transplant outcome, correlated with the increasing MFI value and with the ability of such antibody to fix the complement fraction. Anti-platelet antibodies (anti-HLA class I and anti-HPA [Human Platelet Antigen]) are better involved in transfusion inefficiency and can be responsible for refractory status.

Characterization of the novel HLA-DQA1*05:05:05 allele by sequencing-based typing.

HLA-DQA1*05:05:05 differs from HLA-DQA1*05:05:01:07 by one nucleotide substitution in codon 111 in exon 3.

Characterization of the novel HLA-A*26:199 allele by sequencing-based typing.

HLA-A*26:199 differs from HLA-A*26:01:01:01 by one nucleotide substitution in codon 261 in exon 4.

Characterization of the novel HLA-DQA1*01:49 allele by sequencing-based typing.

HLA-DQA1*01:49 differs from HLA-DQA1*01:01:01:06 by one nucleotide substitution in codon 9 in exon 2.

Characterization of the novel HLA-DPA1*01:03:19 allele by sequencing-based typing.

HLA-DPA1*01:03:19 differs from DPA1*01:03:01:02 by one nucleotide substitution in codon 190 in exon 4.

Characterization of the novel HLA-DRB3*02:02:23 allele by sequencing-based typing.

HLA-DRB3*02:02:23 differs from HLA-DRB3*02:02:01:02 by one nucleotide substitution in codon 218 in exon 4.

Evaluation of the AllType kit for HLA typing using the Ion Torrent S5 XL platform.

HLA genotyping by next-generation sequencing is now widely performed. We aimed at evaluating the performance of the One Lambda AllType kit using Thermo Fisher Scientific reagents on the Ion S5 XL platform. Reads were analyzed using the TypeStream Visual software.

Characterization of the novel HLA-DRB3*02:96 allele by sequencing-based typing.

HLA-DRB3*02:96 differs from HLA-DRB3*02:02:01:01 by one nucleotide substitution in codon 189 in exon 4.

Characterization of the novel HLA-DPA1*02:15 allele by sequencing-based typing.

HLA-DPA1*02:15 differs from HLA-DPA1*02:06 by one nucleotide substitution in codon 218 in exon 4.